Statins may help stabilize the atherosclerotic plaque in acute myocardial infarction. 103 patients who underwent primary angioplasty followed by coronary intravascular ultrasound (IVUS) in the culprit artery and not culprit of infarction were included. Patients received 20 mg of rosuvastatin for two weeks and then 40 mg for 13 months ending up with a new<a href="https://solaci.org/en/2015/06/24/ibis-4-intensive-treatment-with-statins-after-st-segment-elevation-myocardial-infarction/" title="Read more" >...</a>

The benefit of myocardial revascularization (angioplasty or surgery) guided by fractional flow reserve (FFR) in the context of acute coronary syndromes is poorly studied in the literature. The aim of this study was to compare myocardial revascularization guided by FFR versus Angiography in patients admitted suffering a non-ST segment elevation myocardial infarction. 350 patients were<a href="https://solaci.org/en/2015/06/24/famous-nstemi-ffr-versus-angiography-in-non-st-segment-elevation-myocardial-infarction/" title="Read more" >...</a>

This study randomized 1: 1 patient who had been hospitalized for acute coronary syndrome within 30 days after entry to darapladib versus placebo study. A total of 6504 patients were included in the darapladib group and 6522 in the placebo group. At a mean of 2.5 years follow-up a combined cardiovascular events rate was observed,<a href="https://solaci.org/en/2015/06/24/solid-timi-52-darapladib-to-reduce-new-cardiovascular-events-after-myocardial-infarction/" title="Read more" >...</a>

Platelet inhibition is critical in reducing atherothrombotic risk in the short and long term after an acute coronary syndrome, especially if the patient has received coronary angioplasty. Few data are available in the real world in terms of safety and efficacy of prasugrel versus clopidogrel in this clinical context. This registry involved 12227 patients undergoing<a href="https://solaci.org/en/2015/06/24/translate-acs-one-year-prasugrel-versus-clopidogrel-after-acute-coronary-syndrome/" title="Read more" >...</a>

This study was designed to compare the apposition and neointimal coverage of struts by optical coherence tomography (OCT) of the new self-expanding sirolimus &nbsp;eluting stent (STENTYS SES) at 4 and 9 months in patients with STE-ACS. 152 patients randomized to STENTYS SES (n = 90) versus zotarolimus-eluting balloon-expandable stent (n = 62) were included. The<a href="https://solaci.org/en/2015/06/24/apposition-iv-self-expanding-des-in-acute-coronary-syndrome/" title="Read more" >...</a>

This randomized, double-blind, placebo-controlled, multicenter work evaluated the potential cardiovascular reduction risk and the long-term safety profile of Aleglitazar, compared with placebo in patients with type 2 diabetes experiencing an acute coronary syndrome. A total of 7226 patients were randomized at 12 weeks post-acute coronary event to receive Aleglitazar 150 ug or placebo. The study<a href="https://solaci.org/en/2015/06/24/alecardio-trial-aleglitazar-associated-with-severe-adverse-events-in-diabetic-patients-with-acute-coronary-syndrome/" title="Read more" >...</a>

There is evidence that inflammation would have an impact on the prognosis of patients experiencing acute coronary syndromes. The phospholipase A2 inhibitor Varespladib has positive effects on lipid and inflammatory markers. This double-blind, multicenter planned to randomize 5145 patients with acute coronary syndrome to Varespladib or placebo. The primary endpoint was a combination of cardiovascular<a href="https://solaci.org/en/2015/06/24/vista-16-anti-inflammatory-agent-in-acute-coronary-syndromes/" title="Read more" >...</a>

This study randomized 120 patients with acute myocardial infarction after successful primary angioplasty with a residual ejection fraction (LVEF) &lt;45%. An intracoronary infusion with fixed doses of bone marrow derived stem cells vs. placebo was administered (randomization 2:1) 3 days after infarction vs. 7 (randomization 1:1). The objective was to assess ventricular and contractile function<a href="https://solaci.org/en/2015/06/24/time-use-and-duration-of-bone-marrow-derived-stem-cells-infusion-for-the-treatment-of-post-infarction-ventricular-dysfunction/" title="Read more" >...</a>

P-selectin is an adhesion molecule involved in the interactions between endothelial cells, platelets and leukocytes. Inclacumab is a recombinant monoclonal antibody against P-selectin, a potential anti-inflammatory, anti-thrombotic and anti-atherogenic. The objective of the SELECT-ACS was to evaluate whether Inclacumab could reduce myocardial damage during percutaneous coronary intervention (PCI) in patients with non-ST elevation myocardial infarction<a href="https://solaci.org/en/2015/06/24/select-acs-the-inclacumab-seems-to-reduce-myocardial-injury-post-angioplasty/" title="Read more" >...</a>

The aim of this study was to determine whether patients without ST-segment elevation acute coronary syndromes who were not taking statins previously, can receive high doses of rosuvastatin before coronary angiography or angioplasty and if this action could exert protection in renal function and reduce the incidence of contrast-induced nephropathy (CIN). This prospective study randomized<a href="https://solaci.org/en/2015/06/24/prato-acs-rosuvastatin-reduces-the-incidence-of-contrast-nephropathy-in-patients-with-acute-coronary-syndrome-who-receive-early-invasive-strategy/" title="Read more" >...</a>